Healthcare, Pharma & Life Sciences

Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Image
Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

SUANNUTRA Localizes Lemon Verbena Supply Chain in Valencia, Spain

Image
SUANNUTRA Localizes Lemon Verbena Supply Chain in Valencia, Spain

Madrid – September 30, 2026 -- SUANNUTRA SA has relocated cultivation of lemon verbena, a key botanical input for its branded ingredients, from South America to farms in Valencia, Spain, aiming to secure a more resilient and traceable supply chain.

SUANNUTRA shifts lemon verbena sourcing from the Andes to Valencia farms

The plant, native to South America and traditionally used by Andean healers as a digestive aid and antispasmodic remedy, now anchors three of SUANNUTRA's branded ingredients: Metabolaid®, RelaxPLX®, and Elissara®. "Growing it locally with full control from planting to final product reinforces our commitment to responsible botanical sourcing," said Jaime Durán Sanz, Chief Business Officer for SUANNUTRA.

Servier Standardizes Data Across 80+ Countries With Veeva OpenData

Image
Servier Standardizes Data Across 80+ Countries With Veeva OpenData

Barcelona – September 30, 2026 -- Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, part of a global push to build an AI-ready data foundation for its commercial and medical teams.

Servier scales AI infrastructure after prior success with Veeva Link Key People

The French pharmaceutical company, governed by a Foundation, is harmonizing customer reference data globally to create a unified semantic layer that connects with Veeva Link. Liam Hanrahan, director of world operations excellence at Servier, said the move goes beyond process improvement, calling it the construction of a global data foundation designed to redefine how the company operates and scale AI across its affiliates.

Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Image
Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

Image
Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.

Astrocyte Raises $9.5M Series B as Concussion Drug Trial Completes Enrollment

Image
Astrocyte Raises $9.5M Series B as Concussion Drug Trial Completes Enrollment

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

DeepWork Capital leads financing with four new investors joining the round

The Series B was led by DeepWork Capital, with continued backing from existing investors and new participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures. Jackson Streeter, M.D., Venture Partner at DeepWork Capital, said the firm has been impressed by the consistency of Astrocyte's science and the progress of its clinical programs.

EQT Foundation Funds €1M for 11 Brain Drug-Delivery Projects

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

Clarenta Group Acquires Majority Stake in Paris-Based L2D

Image
Clarenta Group Acquires Majority Stake in Paris-Based L2D

London – September 30, 2026 -- Clarenta Group has taken a majority stake in Leads To Development (L2D), a Paris-based preclinical and regulatory consultancy, expanding its reach into early-stage drug development ahead of first-in-human trials.

Clarenta adds non-clinical and manufacturing expertise to its clinical development platform

L2D specializes in defining development pathways, assessing preclinical evidence, troubleshooting manufacturing processes, and building regulatory strategies for biotech and pharmaceutical sponsors. The addition connects this early-stage scientific work directly to Clarenta's existing Early Phase Unit and clinical consulting capabilities.

Insilico Medicine Nominates AI-Designed GIPR Antagonist ISM1354

Image
Insilico Medicine Nominates AI-Designed GIPR Antagonist ISM1354

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676
The company nominated ISM0676, a prior GIPR antagonist, in January, which showed up to 31.3% weight loss in combination with Semaglutide in humanized mouse models. ISM1354 retains comparable weight-loss efficacy while delivering improved pharmacokinetic and safety profiles, addressing tolerability issues that have derailed rival GIPR programs industry-wide.

Roche Unit Launches Triple Newborn Screening Test for SMA, SCID, SCD

Image
Roche Unit Launches Triple Newborn Screening Test for SMA, SCID, SCD

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Single kit consolidates three critical newborn screening panels for hospital labs

The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.